137 related articles for article (PubMed ID: 38707131)
1. Real-World Assessment of Personalized Approach With Voglibose Fixed-Dose Combination in Type 2 Diabetes Mellitus.
Parmar N; Gupta AK; Jhaveri K; A B; Chhaya G; Kansara S; Nair R; Korukonda KR
Cureus; 2024 Apr; 16(4):e57494. PubMed ID: 38707131
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Observational Study on Assessing Sitagliptin and Dapagliflozin as a Fixed-Dose Combination in the Indian Population With Type 2 Diabetes Mellitus: The SIDAXA Study.
Chawla M; Panneerselvam D; Gundgurthy A; Sud S; Alamchandani R; Aneja P; Nair R; Korukonda KR
Cureus; 2024 May; 16(5):e60815. PubMed ID: 38910691
[TBL] [Abstract][Full Text] [Related]
3. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
[TBL] [Abstract][Full Text] [Related]
4. Evaluating Glycemic Control in Patients of South Asian Origin With Type 2 Diabetes Using a Digital Therapeutic Platform: Analysis of Real-World Data.
Krishnakumar A; Verma R; Chawla R; Sosale A; Saboo B; Joshi S; Shaikh M; Shah A; Kolwankar S; Mattoo V
J Med Internet Res; 2021 Mar; 23(3):e17908. PubMed ID: 33764306
[TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of a Digital Therapeutic Intervention in Indian Patients With Type 2 Diabetes Mellitus: 12-Week Prospective Single-Arm Intervention Study.
Chawla R; Jaggi S; Gupta A; Bantwal G; Patil S
JMIR Diabetes; 2022 Oct; 7(4):e41401. PubMed ID: 36226840
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy.
Kumar A; Prakash AS
J ASEAN Fed Endocr Soc; 2019; 34(1):87-91. PubMed ID: 33442141
[TBL] [Abstract][Full Text] [Related]
7. The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population.
Bhattacharjee R; Rai M; Joshi P; Prasad A; Birla A
Cureus; 2023 Oct; 15(10):e46767. PubMed ID: 37954782
[TBL] [Abstract][Full Text] [Related]
8. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice.
Hammer H; Klinge A
Int J Clin Pract; 2007 Dec; 61(12):2009-18. PubMed ID: 17997807
[TBL] [Abstract][Full Text] [Related]
9. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
Gupta A
Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
[TBL] [Abstract][Full Text] [Related]
12. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Mohan V; Ramu M; Poongothai S; Kasthuri S
J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose.
Kasthuri S; Poongothai S; Anjana RM; Selvakumar J; Muthukumar S; Kayalvizhi S; Tariq S; Honey E; Gupta PK; Venkatesan U; Mohan V
Diabetes Technol Ther; 2021 Mar; 23(3):213-220. PubMed ID: 32916063
[No Abstract] [Full Text] [Related]
14. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
Gillani SW; Moosvi AF
Curr Pharm Des; 2020; 26(34):4315-4322. PubMed ID: 32268860
[TBL] [Abstract][Full Text] [Related]
15. Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2).
Ghosh S; Tiwaskar M; Chawla R; Jaggi S; Asirvatham A; Panikar V
Diabetes Ther; 2020 Oct; 11(10):2257-2268. PubMed ID: 32779100
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study.
Balaji V
Indian J Endocrinol Metab; 2013 Jul; 17(4):709-15. PubMed ID: 23961491
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
[TBL] [Abstract][Full Text] [Related]
19. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Moelands SV; Lucassen PL; Akkermans RP; De Grauw WJ; Van de Laar FA
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD005061. PubMed ID: 30592787
[TBL] [Abstract][Full Text] [Related]
20. FASTING VERSUS POSTPRANDIAL HYPERGLYCEMIA AS A TREATMENT TARGET TO LOWER ELEVATED HEMOGLOBIN A1C.
Shaefer C; Reid T; Vlajnic A; Zhou R; DiGenio A
Endocr Pract; 2015 Dec; 21(12):1323-32. PubMed ID: 26307902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
